Literature DB >> 15934923

Notch: a unique therapeutic target for immunomodulation.

Grahame J McKenzie1, Mamnunur Khan, Emmanuel Briend, Yvette Stallwood, Brian R Champion.   

Abstract

Under normal circumstances, the adaptive immune response to either self or harmless antigens is kept under tight control by a combination of deletion mechanisms in the central immune system, and by a system of regulatory cells in the periphery. Together, these control mechanisms enforce a state referred to as immunological tolerance. Breakdown of these mechanisms lead to a variety of immunological disease states involving persistent immune-mediated pathologies. Whereas the processes inducing central tolerance in the immune system are well documented, the mechanisms by which peripheral regulatory cells function are still unclear. Recent publications have reported an unexpected role for the Notch pathway, itself a classical regulator of cell fate, in the development of regulatory T cells. These exciting data demonstrate that Notch signals modulate events downstream of the T cell receptor, diverting T cell differentiation into alternative fates which regulate immune responses in an antigen-specific manner. The Notch pathway is, therefore, uniquely positioned in the developmental pathways leading to regulatory T cells. In this review, the authors discuss the data surrounding the role of Notch in the peripheral immune system, and discuss how this pathway might be manipulated for the treatment of immunological disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15934923     DOI: 10.1517/14728222.9.2.395

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  5 in total

1.  EBNA-3B- and EBNA-3C-regulated cellular genes in Epstein-Barr virus-immortalized lymphoblastoid cell lines.

Authors:  Adrienne Chen; Bo Zhao; Elliott Kieff; Jon C Aster; Fred Wang
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 2.  Notch signaling in diabetic nephropathy.

Authors:  Ramon Bonegio; Katalin Susztak
Journal:  Exp Cell Res       Date:  2012-03-05       Impact factor: 3.905

Review 3.  Engineering dendritic cells to enhance cancer immunotherapy.

Authors:  Jeanette E Boudreau; Aude Bonehill; Kris Thielemans; Yonghong Wan
Journal:  Mol Ther       Date:  2011-04-05       Impact factor: 11.454

4.  DNA and protein co-administration induces tolerogenic dendritic cells through DC-SIGN mediated negative signals.

Authors:  Jinyao Li; Shuang Geng; Xiuping Liu; Hu Liu; Huali Jin; Chang-Gong Liu; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2013-06-04       Impact factor: 3.452

Review 5.  Targeting the Notch Signaling Pathway in Chronic Inflammatory Diseases.

Authors:  Panagiotis F Christopoulos; Torleif T Gjølberg; Stig Krüger; Guttorm Haraldsen; Jan Terje Andersen; Eirik Sundlisæter
Journal:  Front Immunol       Date:  2021-04-12       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.